Cargando…
Prospective clinical validation of 3D printed nasopharyngeal swabs for diagnosis of COVID-19
COVID-19 greatly disrupted the global supply chain of nasopharyngeal swabs, and thus new products have come to market with little data to support their use. In this prospective study, 2 new 3D printed nasopharyngeal swab designs were evaluated against the standard, flocked nasopharyngeal swab for th...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577894/ https://www.ncbi.nlm.nih.gov/pubmed/33220640 http://dx.doi.org/10.1016/j.diagmicrobio.2020.115257 |
_version_ | 1783598268045852672 |
---|---|
author | Oland, Gabriel Garner, Omai de St Maurice, Annabelle |
author_facet | Oland, Gabriel Garner, Omai de St Maurice, Annabelle |
author_sort | Oland, Gabriel |
collection | PubMed |
description | COVID-19 greatly disrupted the global supply chain of nasopharyngeal swabs, and thus new products have come to market with little data to support their use. In this prospective study, 2 new 3D printed nasopharyngeal swab designs were evaluated against the standard, flocked nasopharyngeal swab for the diagnosis of COVID-19. Seventy adult patients (37 COVID-positive and 33 COVID-negative) underwent consecutive diagnostic reverse transcription polymerase chain reaction testing, with a flocked swab followed by one or two 3D printed swabs. The “Lattice Swab” (manufacturer Resolution Medical) demonstrated 93.3% sensitivity (95% CI, 77.9%–99.2%) and 96.8% specificity (83.3%–99.9%), yielding κ = 0.90 (0.85–0.96). The “Origin KXG” (manufacturer Origin Laboratories) demonstrated 83.9% sensitivity (66.3%–94.6%) and 100% specificity (88.8%–100.0%), yielding κ = 0.84 (0.77–0.91). Both 3D printed nasopharyngeal swab results have high concordance with the control swab results. The decision to use 3D printed nasopharyngeal swabs during the COVID-19 pandemic should be strongly considered by clinical and research laboratories. |
format | Online Article Text |
id | pubmed-7577894 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75778942020-10-22 Prospective clinical validation of 3D printed nasopharyngeal swabs for diagnosis of COVID-19 Oland, Gabriel Garner, Omai de St Maurice, Annabelle Diagn Microbiol Infect Dis Article COVID-19 greatly disrupted the global supply chain of nasopharyngeal swabs, and thus new products have come to market with little data to support their use. In this prospective study, 2 new 3D printed nasopharyngeal swab designs were evaluated against the standard, flocked nasopharyngeal swab for the diagnosis of COVID-19. Seventy adult patients (37 COVID-positive and 33 COVID-negative) underwent consecutive diagnostic reverse transcription polymerase chain reaction testing, with a flocked swab followed by one or two 3D printed swabs. The “Lattice Swab” (manufacturer Resolution Medical) demonstrated 93.3% sensitivity (95% CI, 77.9%–99.2%) and 96.8% specificity (83.3%–99.9%), yielding κ = 0.90 (0.85–0.96). The “Origin KXG” (manufacturer Origin Laboratories) demonstrated 83.9% sensitivity (66.3%–94.6%) and 100% specificity (88.8%–100.0%), yielding κ = 0.84 (0.77–0.91). Both 3D printed nasopharyngeal swab results have high concordance with the control swab results. The decision to use 3D printed nasopharyngeal swabs during the COVID-19 pandemic should be strongly considered by clinical and research laboratories. Elsevier Inc. 2021-03 2020-10-22 /pmc/articles/PMC7577894/ /pubmed/33220640 http://dx.doi.org/10.1016/j.diagmicrobio.2020.115257 Text en © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Oland, Gabriel Garner, Omai de St Maurice, Annabelle Prospective clinical validation of 3D printed nasopharyngeal swabs for diagnosis of COVID-19 |
title | Prospective clinical validation of 3D printed nasopharyngeal swabs for diagnosis of COVID-19 |
title_full | Prospective clinical validation of 3D printed nasopharyngeal swabs for diagnosis of COVID-19 |
title_fullStr | Prospective clinical validation of 3D printed nasopharyngeal swabs for diagnosis of COVID-19 |
title_full_unstemmed | Prospective clinical validation of 3D printed nasopharyngeal swabs for diagnosis of COVID-19 |
title_short | Prospective clinical validation of 3D printed nasopharyngeal swabs for diagnosis of COVID-19 |
title_sort | prospective clinical validation of 3d printed nasopharyngeal swabs for diagnosis of covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577894/ https://www.ncbi.nlm.nih.gov/pubmed/33220640 http://dx.doi.org/10.1016/j.diagmicrobio.2020.115257 |
work_keys_str_mv | AT olandgabriel prospectiveclinicalvalidationof3dprintednasopharyngealswabsfordiagnosisofcovid19 AT garneromai prospectiveclinicalvalidationof3dprintednasopharyngealswabsfordiagnosisofcovid19 AT destmauriceannabelle prospectiveclinicalvalidationof3dprintednasopharyngealswabsfordiagnosisofcovid19 |